Amedisys Inc (NASDAQ:AMED) – Jefferies Financial Group boosted their Q1 2020 earnings per share estimates for shares of Amedisys in a research note issued to investors on Monday. Jefferies Financial Group analyst L. Allir now anticipates that the company will post earnings per share of $0.96 for the quarter, up from their prior forecast of $0.91. Jefferies Financial Group has a “Buy” rating and a $74.00 price objective on the stock. Jefferies Financial Group also issued estimates for Amedisys’ Q2 2020 earnings at $0.96 EPS, Q3 2020 earnings at $0.93 EPS, Q4 2020 earnings at $0.96 EPS, FY2020 earnings at $3.63 EPS, FY2021 earnings at $3.73 EPS, FY2022 earnings at $3.80 EPS and FY2023 earnings at $3.90 EPS.
Get Amedisys alerts:
AMED has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a research report on Tuesday, March 5th. Cowen set a $76.00 price objective on shares of Amedisys and gave the stock a “buy” rating in a research report on Thursday, March 1st. Finally, Morgan Stanley restated an “equal weight” rating and issued a $71.00 price objective (up previously from $63.00) on shares of Amedisys in a research report on Tuesday, March 5th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $64.80.
In other news, Director Taylor Carol Montrde sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, March 28th. The shares were sold at an average price of $64.76, for a total value of $966,800.00. Following the completion of the sale, the director now directly owns 9,387 shares in the company, valued at approximately $656,486.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink . Also, CFO David Zito sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $61.09, for a total transaction of $920,900.00. Following the completion of the sale, the chief financial officer now owns 20,774 shares of the company’s stock, valued at $1,203,962.27. The disclosure for this sale can be found here . Insiders sold a total of 74,842 shares of company stock valued at $4,731,755 over the last 90 days. 4.90% of the stock is currently owned by company insiders.
Amedisys (NASDAQ:AMED) opened at $63.79 on Wednesday. The company has a market cap of $1,660.00, a P/E ratio of 22.64, a PEG ratio of 1.65 and a beta of 0.51. Amedisys has a fifty-two week low of $49.61 and a fifty-two week high of $75.89.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $0.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.86 by $0.04. The firm had revenue of $441.90 million during the quarter, compared to the consensus estimate of $434.07 million. Amedisys had a net margin of 3.17% and a return on equity of 19.96%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.92 EPS.
A number of hedge funds have recently made changes to their positions in the business. Teachers Advisors LLC grew its position in Amedisys by 4.4% during the 4th quarter. Teachers Advisors LLC now owns 106,881 shares of the company’s stock valued at $5,152,